Debu Tripathy, M. D., UT Southwestern Medical School, Professor of Medicine

Debu Tripathy, M. D., is a Professor of Medicine and Director of the Komen/UTSW Breast Cancer Research Program at the University of Texas Southwestern Medical Center at Dallas. His past laboratory research has focused on the role of receptor tyrosine kinase oncogene products in human breast cancer, including the use of anti-sense gene technology to interfere with oncogene expression. He has also characterized mechanisms of induction of metastases-related proteins such as urokinase, its receptor and inhibitor in human breast cancer cells.

Dr. Tripathy received his medical degree from Duke University School of Medicine in Durham, North Carolina, and completed an internship and residency at Duke University Medical Center. After a clinical fellowship in hematology and oncology, he completed a postdoctoral fellowship at the Cancer Research Institute, University of California at San Francisco. He is a member of the American Society of Clinical Oncology, the American Association for the Advancement of Science, and is Immediate-Past President of the American Society of Breast Diseases.

Dr. Tripathy maintains a university-based oncology clinical practice primarily in breast cancer, and he serves as principal investigator on several regional and national clinical trials as well as laboratory-based projects. He is currently interested in conducting clinical research in the field of breast cancer that emphasizes standard as well as innovative approaches derived in the laboratory. Recently, these have included targeted therapy against the HER-2/neu oncogene and other growth factor receptors, new hormonal therapies, and a series of preclinical and clinical studies on botanical agents. He is also conducting correlative studies aimed at defining cancer gene and protein profiles that correlate with response to conventional and novel therapeutics.

< < Return